11th week of 2014 patent applcation highlights part 49 |
Patent application number | Title | Published |
20140073635 | Substituted Imidazopyridinyl-Aminopyridine Compounds - The present invention relates to substituted imidazopyridinyl-aminopyridine compounds and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing substituted imidazopyridinyl-aminopyridine compounds and methods of treating cell proliferative disorders, such as cancer, by administering these compounds and pharmaceutical compositions to subjects in need thereof. | 2014-03-13 |
20140073636 | NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS - Compounds of the formula Ia***** | 2014-03-13 |
20140073637 | AMINO-SUBSTITUTED-ALKYLOXY-BENZO[E]PYRIDO[4,3-B]INDOLE DERIVATIVES AS NEW POTENT KINASE INHIBITORS - The present invention relates to a new class of benzo[e]pyrido-indole, the amino-substituted-alkyloxy-benzo[e]pyrido[4,3-b]indole derivatives, having a particular kinase inhibition profile and useful as a therapeutic agent, in particular an anti-tumoral agent. | 2014-03-13 |
20140073638 | ETHYNYL COMPOUNDS USEFUL FOR TREATMENT OF CNS DISORDER - The present invention relates to ethynyl compounds of formula | 2014-03-13 |
20140073639 | INHIBITION OF ANTIMICROBIAL TARGETS WITH REDUCED POTENTIAL FOR RESISTANCE - The application describes targets and methods that can inhibit bacterial growth in Gram-positive and Gram-negative bacteria. A bacterial enzyme, 2-epimerase, is common to both Gram-positive and Gram-negative bacteria and contains an allosteric site that can be targeted to disrupt the enzyme. The allosteric site is present on the bacterial 2-epimerase, but the analogous mammalian enzyme does not contain the allosteric site, providing a route for attacking bacterial infections without affecting the mammalian enzyme. | 2014-03-13 |
20140073640 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES - Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein. | 2014-03-13 |
20140073641 | 1-HETEROCYCLYL-1,5-DIHYDRO-PYRAZOLO[3,4-D] PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MODULATORS - The invention relates to novel 1,6-disubstituted pyrazolopyrimidinones, wherein i.) the nitrogen atom of the pyrazolo-group that is next to the pyrimidino-group is attached to a non-aromatic, organic heterocycle having at least one ring hetero atom selected from O, N and S and ii.) to the C-atom between the two nitrogen atoms of the pyrimidinone-ring a second substituent is bound via an optionally substituted methylene-bridge. According to one aspect of the invention the new compounds are for the manufacture of medicaments, in particular medicaments for the treatment of conditions concerning deficits in perception, concentration, learning or memory. The new compounds are also for the manufacture of medicaments for the treatment of Alzheimer's disease. | 2014-03-13 |
20140073642 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES - This invention relates to quinazoline derivatives, processes for their preparation, pharmaceutical compositions, and their use in therapy of disorders in which the modulation of toll-like-receptors is involved. | 2014-03-13 |
20140073643 | TREATMENT OF JAK2-MEDIATED CONDITIONS - Described herein is a method for treating a subject experiencing anemia, comprising administering to the subject an amount of N-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]-benzamide [CYT387 ] or a related compound effective to maintain or elevate the hemoglobin level. The anemic subjects including those afflicted with a myeloproliferative disorder, such as primary myelofibrosis. | 2014-03-13 |
20140073644 | COMPOSITIONS OF DIBROMOMALONAMIDE AND THEIR USE AS BIOCIDES - A biocidal composition comprising 2,2-dibromomalonamide and an aldehyde-based biocidal compound, and its use for the control of microorganisms in aqueous and water-containing systems. | 2014-03-13 |
20140073645 | Treatment of Solid Tumours - A cell permeable iron chelator, optionally in combination with an autophagy inhibiting agent, is used for treating a solid cancer tumour in a person. A preferred chelator is an alkyl substituted N-(1-pyridine-2-yl-methylidene)-N-(9H-1,3,4,9-tetraaza-fluoren-2-yl)-hydrazine. A preferred autophagy inhibiting agent is chloroquine. Also disclosed is a pharmaceutical composition comprising iron chelator, pharmaceutically acceptable carrier and, optionally, autophagy inhibiting agent; and a method of treating cancer by administering cancer combating-effective amount(s) of the iron chelator or the combination of iron chelator and autophagy inhibiting agent. | 2014-03-13 |
20140073646 | COMPOSITIONS OF DIBROMOMALONAMIDE AND THEIR USE AS BIOCIDES - A biocidal composition comprising 2,2-dibromomalonamide and an aldehyde-based biocidal compound, and its use for the control of microorganisms in aqueous and water-containing systems. | 2014-03-13 |
20140073647 | NOVEL FLUOROERGOLINE ANALOGS - Provided herein are novel fluoroergoline derivatives and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT | 2014-03-13 |
20140073648 | METHODS FOR TREATING IMMUNOLOGIC DISEASE USING AMINOTHIAZOLE-BASED INHIBITOR OF MYD88 - A method of treating an immunologic disease. The method includes administering an aminothiazole-based inhibitor of myeloid differentiation protein 88 (MyD88) to a patient in need thereof. The inhibitor of MyD88 acts as an immunomodulator for treatment of the immunologic disease including but not limited to rejections after organ transplantation, chronic inflammatory diseases, autoimmune diseases, ischemia-reperfusion injuries, and endotoxemia and sepsis. | 2014-03-13 |
20140073649 | ISOTOPICALLY ENRICHED ARYLSULFONAMIDE CCR3 ANTAGONISTS - Provided herein are isotopically enriched arylsulfonamides, for example, of Formula I, that are useful for modulating CCR3 activity, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a CCR3-mediated disease, disorder, or condition. | 2014-03-13 |
20140073650 | PROTEASOME CHYMOTRYPSIN-LIKE INHIBITION USING PI-1833 ANALOGS - Focused library synthesis and medicinal chemistry on an oxadiazole-isopropylamide core proteasome inhibitor provided the lead compound that strongly inhibits CT-L activity. Structure activity relationship studies indicate the amide moiety and two phenyl rings are sensitive toward synthetic modifications. Only para-substitution in the A-ring was important to maintain potent CT-L inhibitory activity. Hydrophobic residues in the A-ring's para-position and meta-pyridyl group at the B-ring significantly improved inhibition. The meta-pyridyl moiety improved cell permeability. The length of the aliphatic chain at the para position of the A-ring is critical with propyl yielding the most potent inhibitor, whereas shorter (i.e. ethyl, methyl or hydrogen) or longer (i.e. butyl, propyl and hexyl) chains demonstrating progressively less potency. Introduction of a stereogenic center next to the ether moiety (i.e. substitution of one of the hydrogens by methyl) demonstrated chiral discrimination in proteasome CT-L activity inhibition (the S-enantiomer was 35-40 fold more potent than the R-enantiomer). | 2014-03-13 |
20140073651 | BENZAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS - The invention relates to benzamide derivatives of formula (I), | 2014-03-13 |
20140073652 | Post-Translational Regulation of Catalytic Activities of Cytochrome P450 46A1 and Uses Thereof - Provided herein are methods and compounds for post-translational regulation of cytochrome P450 46A1 (CYP46A1) enzyme activity in the brain and retina. Also, a method for identifying a potential regulator of a CYP46A1 enzyme using crystal structures of the enzyme and a subsequent method for screening for a regulatory activity in the presence of CYP46A1 enzyme are provided. In addition, the regulator compounds that either inhibit or stimulate cholesterol hydroxylation by the CYP46A1 enzyme are provided. Further provided is a method of treating a pathoneurological condition associated with increased cholesterol levels in the brain and retina using the stimulatory compounds. | 2014-03-13 |
20140073653 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR - The present invention relates to compounds of formula IVA, formula IVB, or formula IVC, useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating diseases using such CFTR modulators. | 2014-03-13 |
20140073654 | METHODS FOR DETECTION OF BIOLOGICAL SUBSTANCES - The invention is directed to a method of detecting a biological substance in the nasal secretion and diagnosing a disease following the detection of the biological substance wherein the biological substance is not related to a respiratory disease. The invention also provides treatment of the diseases following the detection of the biological substance and/or diagnosis of the disease. In some embodiments, the diseases are cancer, hepatitis, smell loss, taste loss, diabetes, and leprosy. The invention also provides a kit for diagnosing a disease. | 2014-03-13 |
20140073655 | METHOD FOR TREATING FATIGUE - The present invention refers to an active moiety of | 2014-03-13 |
20140073656 | SERMS for the Treatment of Estrogen Receptor-Mediated Disorders - Novel compounds for the treatment of estrogen receptor-mediated disorders, including breast cancer, and methods of treatment using the novel compounds. The novel compounds, when administered in a safe and effective amount, present extended binding to estrogen receptors in breast tissue without activating the estrogen receptors. Estrogen is blocked from binding to the estrogen receptors for an extended period of time, effectively hindering growth of breast cancer cells. | 2014-03-13 |
20140073657 | 3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]OCTANE- OR HEPTANE-NITRILE AS JAK INHIBITORS - The present invention relates to the Janus kinase (JAK) inhibitors 3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]octanenitrile or 3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]heptanenitrile, as well as its compositions and methods of use, which is useful in the treatment of JAK-associated diseases including, for example, inflammatory and autoimmune disorders, skin disorders, cancer, and other diseases. | 2014-03-13 |
20140073658 | Dipyridylamine Derivative - Disclosed herein are compounds, or pharmacologically acceptable salts thereof, having glucokinase activating activity. In various aspects, the compounds are represented by general formula (I), or pharmacologically acceptable salts thereof: | 2014-03-13 |
20140073659 | TREATMENT FOR VITILIGO - Compounds I and II, as well as prodrugs, hydrates, solvates, N-oxides, salts and pharmaceutical compositions containing them, are useful for treating vitiligo. In certain embodiments, the compounds are provided in topical compositions. | 2014-03-13 |
20140073660 | Pyrimidylaminobenzamide Derivatives for Treatment of Neurofibromatosis - The present invention relates to the use of pyrimidylamlnobenzamide derivatives for the preparation of a drug for the treatment of non-cancerous, benign brain tumors, especially for the curative and/or prophylactic treatment of NF, and to a method of treating non-cancerous, benign brain tumors, especially for the curative and/or prophylactic treatment of NF. | 2014-03-13 |
20140073661 | HETEROCYCLIC COMPOUNDS AND USES THEREOF - The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same. | 2014-03-13 |
20140073662 | Spirocyclic nitriles as protease inhibitors - The invention relates to substituted carbo- and heterocyclic spiro compounds of the formula Ia which inhibit thiol proteases, to processes for their preparation and to the use thereof as medicaments. | 2014-03-13 |
20140073663 | METHOD OF PROVIDING SUSTAINED ANALGESIA WITH BUPRENORPHINE - A method of effectively treating pain in humans is achieved by administering buprenorphine in accordance with first order kinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an additional two-day dosing interval in accordance with substantially zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval. | 2014-03-13 |
20140073664 | Combination Dopamine Antagonist and Opiate Receptor Antagonist Treatment of Addictive Behavior - The present invention is directed to a method of treating or preventing an addictive behavior in a subject, said method comprising administering to said subject an effective amount of a dopamine antagonist and a opiate receptor antagonist or a composition comprising same. Further provided are pharmaceutical compositions comprising, as active substances, at least one dopamine antagonist and at least one opiate receptor antagonist. | 2014-03-13 |
20140073665 | MODIFIED RELEASE COMPOSITIONS COMPRISING TACROLIMUS - A modified release composition comprising tacrolimus which is useful for the treatment or prevention of rejection reactions by transplantation of organs or tissues. | 2014-03-13 |
20140073666 | COMPOSITIONS AND METHODS FOR TREATMENT - The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists. | 2014-03-13 |
20140073667 | DEUTERATED CFTR POTENTIATORS - This invention relates to compounds of Formula I: | 2014-03-13 |
20140073668 | N-QUINOLIN-BENZENSULFONAMIDES AND RELATED COMPOUNDS FOR THE TREATMENT OF CANCER, AUTOIMMUNE DISORDERS AND INFLAMMATION - The present invention relates to the NQBS class of molecules. It is based, at least in part, on the discovery that a representative group of compounds have been observed to inhibit nuclear translocation of NF-κB subunits. Without being bound by any particular theory, this inhibition of nuclear translocation may be mediated by either (i) binding of the NQBS or related compound to the C-terminus of the RHD, which specifically mediates the nuclear internalization; or (ii) NQBS-mediated stabilization of the dimer/IκB complex, disallowing dissociation of the active NF-κB monomers, and thus, inhibiting the generation of the subunits necessary to enter the nucleus. The NQBS class of molecules, and related molecules, may be used in therapeutic applications where inhibition of NF-κB translocation is beneficial, including but not limited to the treatment of cancer, autoimmune disorders, and inflammatory states. | 2014-03-13 |
20140073669 | 4'-O-SUBSTITUTED ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME - Provided are 4′-O substituted isoindoline compounds, and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed. | 2014-03-13 |
20140073670 | PHARMACEUTICAL COMPOSITION COMPRISING FEXOFENADINE - The present invention relates to a pharmaceutical formulation of fexofenadine hydrochloride in a solvent system suitable as a liquid fill composition. | 2014-03-13 |
20140073671 | ORALLY DISINTEGRATING TABLET - Provided is an orally disintegrating tablet comprising a bitter-tasting pharmaceutically active ingredient in the form of bepotastine or a pharmacologically acceptable salt thereof that enables the bitter taste thereof to be masked, has both superior oral cavity disintegration and adequate hardness, and can be produced with ordinary tablet production equipment. The present invention relates to an orally disintegrating tablet containing bepotastine or a pharmacologically acceptable salt thereof, menthol or cyclodextrin, a water-insoluble polymer, and a disintegrating agent; and a method for producing an orally disintegrating tablet, comprising: 1) a step for obtaining granulated granules by mixing and granulating bepotastine or a pharmacologically acceptable salt thereof, a water-insoluble polymer, and optionally a vehicle, 2) a step for obtaining granules for tableting by mixing the granulated granules, menthol, a disintegrating agent, and optionally a lubricant and/or sweetener, and 3) a step for compressing the granules for tableting. | 2014-03-13 |
20140073672 | NOVEL PYRAZOLONE-DERIVATIVES AND THEIR USE AS PDE-4 INHIBITORS - The compounds of Formula (I), | 2014-03-13 |
20140073673 | Pirfenidone Treatment for Patients with Atypical Liver Function - Methods are provided for administering pirfenidone to a patient that has exhibited abnormal biomarkers of liver function in response to pirfenidone administration. The methods include administering to a patient pirfenidone at doses lower than the full target dosage for a time period, followed by administering to the patient pirfenidone at the full target dosage. The methods also include administering pirfenidone at the full target dose with no reduction and administering permanently reduced doses of pirfenidone. | 2014-03-13 |
20140073674 | COCRYSTALS OF P-COUMARIC ACID - Disclosed herein are cocrystals of p-coumaric acid and nicotinamide. A 1:1 molar ratio and a 2:1 molar ratio of p-coumaric acid to nicotinamide are herein disclosed. | 2014-03-13 |
20140073675 | PLANT PATHOGEN INHIBITOR COMBINATIONS AND METHODS OF USE - Combinations, compositions and methods of use for modulating plant pathogen infection using plant extracts containing anthraquinone derivatives which induce resistance to plant phytopathogens and an antimicrobial agent, a biological control agent and/or a surfactant having fungicidal activity | 2014-03-13 |
20140073676 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES - Since a compound represented by the general formula (I) (wherein definition of each group is as described in the specification), a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc. | 2014-03-13 |
20140073677 | VALSARTAN SALTS - The invention relates to new salts of valsartan or crystalline, also partly crystalline and amorphous salts of valsartan, the respective production and usage, and pharmaceutical preparations containing such a salt. | 2014-03-13 |
20140073678 | ANTI-PAIN AND ANTI-NAUSEA AND/OR VOMITING COMBINATORIAL COMPOSITIONS - In one aspect, the present invention discloses combinational compositions for treating users experiencing symptoms associated with a migraine or other central nervous system related pain disorder that can cause or exacerbate nausea and/or vomiting or other central nervous system related pain disorder that can cause or exacerbate nausea and/or vomiting. The combinational composition includes a first pharmaceutical active component for treating pain, and a second pharmaceutical active component for treating nausea and/or vomiting and/or vomiting in a user. | 2014-03-13 |
20140073679 | CRYSTALLINE N--5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride - An improved AKT inhibiting compound, crystalline N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride. | 2014-03-13 |
20140073680 | BLADDER CANCER TREATMENT AND METHODS - Therapeutic compositions comprising an indoloquinone compound and various bladder cancer treatments and methods are disclosed. More specifically, the compositions comprise an indoloquinone compound and a formulation vehicle. The formulation vehicle improves the solubility and stability of the indoloquinone compound. Additionally, the coating compositions can include coating agents that provide better adhesion of the coating composition to the bladder wall during intravesical delivery of the coating composition. | 2014-03-13 |
20140073681 | METHODS OF TREATING ALZHEIMER'S DISEASE AND PHARMACEUTICAL COMPOSITIONS THEREOF - The present invention describes methods of treating dementia comprising administering an effective daily dose of N-(2-(6-fluoro-1H-indol-3-yl)ethyl-(2,2,3,3-tetrafluoropropoxy)benzylamine to improve or augment the effect of an acetylcholinesterase inhibitor. | 2014-03-13 |
20140073682 | PYRROLIDINE TRIPLE REUPTAKE INHIBITORS - In various embodiments, the present invention provides cycloalkyl pyrrolidine compounds and methods for their use in the treatment and/or prevention of various diseases, conditions and syndromes, including central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter. | 2014-03-13 |
20140073683 | MODIFIED SMALL INTERFERING RNA MOLECULES AND METHODS OF USE - The present invention provides double-stranded RNA molecules that mediate RNA interference in target cells, preferably hepatic cells. The invention also provides double-stranded RNA molecules that are modified to be resistant to nuclease degradation, which inactivates a virus, and more specifically, hepatitis C virus (HCV). The invention also provides a method of using these modified RNA molecules to inactivate virus in mammalian cells and a method of making modified small interfering RNAs (siRNAs) using human Dicer. | 2014-03-13 |
20140073684 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES FOR USE IN MODULATING MICRO RNA AND USES THEREOF - This invention relates generally to chemically modified oligonucleotides useful for modulating expression of microRNAs and pre-microRNAs. More particularly, the invention relates to single stranded chemically modified oligonucleotides for inhibiting microRNA and pre-microRNA expression and to methods of making and using the modified oligonucleotides. Also included in the invention are compositions and methods for silencing microRNAs in the central nervous system. | 2014-03-13 |
20140073685 | METHOD OF INHIBITING NONSENSE-MEDIATED mRNA DECAY - Provided are methods for treating a NAD comprising administering to a patient suffering from a NAD a composition comprising an eIF5A inhibitor compound in an amount effective to prevent intracellular hypusination of eIF5A, whereby gene expression of NMD-susceptible mRNA is increased. | 2014-03-13 |
20140073686 | COMPOSITIONS FOR MODULATING INVASION ABILITY OF A TUMOR AND METHODS THEREOF - The present invention provides a composition for modulating invasion ability of a tumor, comprising: an effective amount of an activator for a miRNA-mediated pathway or an effective amount of a modulating member in the miRNA-mediated pathway being a modulating member, and wherein the miRNA-mediated pathway is regulated by at least one miRNA selected from the group consisting of miR-346, miR-504 and miR-1179. The composition functions according to a novel model that an activator or a modulating member can regulate cellular invasion/migration of tumor via a miRNA-mediated pathway, and thereby can be a potential candidate of molecular drug to treat the tumor by modulating its invasion ability. A method for treating or preventing tumor invasion method is provided as well. Meanwhile, a method for detecting the invasive ability of a tumor in a subject and the kit thereof are also provided. | 2014-03-13 |
20140073687 | EFFICIENT PROTEIN EXPRESSION IN VIVO USING MODIFIED RNA (MOD-RNA) - Aspects of the invention described herein relate to synthetic, modified RNAs and their use in vivo to modulate gene expression. Aspects of the invention further relate to the use of these synthetic, modified RNAs in myocytes, cardiomyoctes, and tumors. | 2014-03-13 |
20140073688 | COMPOUNDS FOR USE IN THE TREATMENT OF FILARIASIS - A compound for use in a therapeutic treatment of filariasis or a prophylactic treatment of filariasis of the general formula (1) | 2014-03-13 |
20140073689 | Crystals of Substituted Cycloalkene Derivatives - To provide potassium salts of substituted pyrrolidine derivatives, which suppress the production of an inflammatory mediator caused by intracellular signal transduction or cell activation induced by endotoxin, and crystals thereof. The present invention provides potassium(2-chloro-4-fluorophenyl){[(2R,3R,8R)-7-(ethoxycarbonyl)-2,3-bis(hydroxymethyl)-1,4-dioxaspiro[4.5]deca-6-en-8-yl]sulfonyl}azanide and potassium(2-bromo-4-fluorophenyl){[(2R,3R,8R)-7-(ethoxycarbonyl)-2,3-bis(hydroxymethyl)-1,4-dioxaspiro[4.5]deca-6-en-8-yl]sulfonyl}azanide, each of which suppresses the production of an inflammatory mediator caused by intracellular signal transduction or cell activation induced by endotoxin, crystals thereof, and a pharmaceutical containing any of the same, and a prophylactic and/or therapeutic agent for sepsis containing any of the same. | 2014-03-13 |
20140073690 | COVALENT INHIBITION OF BACTERIAL QUORUM SENSING - Inhibitors of bacterial communication, such as quorum sensing, and method of use and manufacture thereof. | 2014-03-13 |
20140073691 | Methods and composition for Treating Thyroid Hormone Related Disorders - The invention generally relates to methods of improving thyroid hormone sensitivity or treating a thyroid hormone resistance related disorder in a patient in need thereof, comprising administering a pharmaceutically effective amount of a MetAP-2 inhibitor. Such methods may include administering a MetAP-2 inhibitor at a dose that does not substantially modulate angiogenesis. | 2014-03-13 |
20140073692 | HIGHLY PURIFIED ETHYL EPA AND OTHER EPA DERIVATIVES - A pharmaceutical preparation comprising EPA in an appropriately assimilable form where of all the fatty acids present in the preparation at least 90%, and preferably at least 95%, is in the form of EPA and where less than 5%, and preferably less than 3%, is in the form of DHA is provided. | 2014-03-13 |
20140073693 | USE OF KETONE ESTERS FOR PREVENTION OF CNS OXYGEN TOXICITY - The present invention demonstrates the therapeutic use of ketone esters for seizure disorders, Alzheimer's disease and malignant brain cancer, which are associated with metabolic dysregulation. The administration of ketone esters resulted therapeutic ketosis and neuroprotection against seizures resulting from CNS oxygen toxicity. Supplemental ketones were also found to reduce superoxide production in cultured cortex neurons exposed to hyperbaric oxygen and Aβ-42, and to decrease proliferation and viability in U87 glioma cells. These observations support the therapeutic effect of ketones for seizure disorders, Alzheimer's disease and malignant brain cancer. The ketone esters may be derived from acetoacetate and can include R,S-1,3-butanediol acetoacetate monoester, R,S-1,3-butanediol acetoacetate diester, or a combination of the two. | 2014-03-13 |
20140073694 | CYSTAMINE ANALOGUES FOR THE TREATMENT OF PARKINSON'S DISEASE - The present invention relates to the use of cystamine analogues for the treatment of Parkinson's disease. The present invention also relates to the use of composition comprising cystamine analogues and cysteine. The present invention relates to a method for modifying the progression of Parkinson's disease comprising administering a therapeutically effective amount of at least one cystamine analogue or a pharmaceutically acceptable salt of a cystamine analogue to a patient in need thereof. | 2014-03-13 |
20140073695 | METHOD FOR THE PREPARATION OF A LEVOTHYROXINE SOLUTION - Levothyroxine, also known as L-thyroxine, synthetic T4, or 3,5,3′,5′-tetraiodo-L-thyronine, CAS number 51-48-9, is a synthetic form of thyroxine, used as a hormone substitute for patients with thyroid conditions. The invention relates to a method for the preparation of an oral levothyroxine composition. The method according to the invention results in liquid levothyroxine formulations that have improved storage stability compared to known liquid levothyroxine formulations. | 2014-03-13 |
20140073696 | COMBINATION COMPOSITION - A combination pharmaceutical composition for the treatment of pain including about 125 mg to about 150 mg ibuprofen and about 475 mg to about 500 mg paracetamol. | 2014-03-13 |
20140073697 | DELIVERY OF IBUPROFEN AND OTHER COMPOUNDS - The present invention generally relates to the transdermal delivery of various compositions. In some aspects, the transdermal delivery may be facilitated by the use of a hostile biophysical environment. One set of embodiments provides a composition for topical delivery comprising ibuprofen and/or an ibuprofen salt, a nitric oxide donor, and optionally, a hostile biophysical environment. In some cases, the composition may be stabilized using a stabilization polymer such as xanthan gum, KELTROL® BT and/or KELTROL® RD; propylene glycol; and a polysorbate surfactant such as Polysorbate 20, which unexpectedly provides temperature stability to the composition, e.g., at elevated temperatures such as at least 40° C. (at least about 104° F.), as compared to compositions lacking one or more of these. | 2014-03-13 |
20140073698 | PHARMACEUTICAL COMPOSITION COMPRISING KETOPROFEN - The present invention relates to a pharmaceutical formulation of ketoprofen sodium salts in a hydrophilic solvent system suitable as a liquid fill composition. | 2014-03-13 |
20140073699 | Combination Therapies for the Treatment of Obesity - Described are pharmaceutical compositions comprising phentermine, metformin, and at least one pharmaceutically acceptable carrier or excipient. Another aspect of the present invention relates to a method of treating a patient suffering from obesity or needing to lose weight, comprising the step of co-administering to said patient a therapeutically effective amount of phentermine and metformin. In certain embodiments, an aforementioned method is practiced in conjunction or tandem with a medical procedure or the use of a medical device or both. | 2014-03-13 |
20140073700 | GLYCYRRHETINIC ACID DERIVATIVES AND METHODS OF USE THEREOF - The present application relates to: (a) compounds of Formula (I): | 2014-03-13 |
20140073701 | METHODS OF PREVENTING, TREATING AND DIAGNOSING DISORDERS OF PROTEIN AGGREGATION - Disclosed are methods of preventing, treating, or diagnosing in a subject a disorder in protein folding or aggregation, or amyloid formation, deposition, accumulation, or persistence consisting of administering to said subject a pharmaceutically effective amount of inositol stereoisomers, enantiomers or derivatives thereof. | 2014-03-13 |
20140073702 | LUPEOL ANTI-TUMOR AGENT AND USES THEREOF - Methods for the prevention, treatment and/or alleviation of skin disorders and skin cancers, and for the prevention, treatment and/or alleviation of prostate cancer and pancreatic cancer by administering a Lupeol-derived anti-tumor compound are disclosed. Pharmaceutical and nutraceutical compositions containing Lupeol-derived anti-tumor compounds are also disclosed. | 2014-03-13 |
20140073703 | PHYTOL AS A CHOLESTEROL LOWERING AGENT - Phytol (3,7,11,15-Tetramethyl-2-hexadecen-1-ol),orderivates thereof, of natural or synthetic origin are used as active ingredient in formulations to lower serum levels of triglycerides and/or cholesterol. Phytol can be administered to patients with disease conditions related to increased levels of cholesterol or triglycerides such as type II diabetes, obesity or other patients in risk of cardiovascular diseases due to elevated cholesterol levels. Phytol can also be administered to healthy individuals to maintain normal levels of serum cholesterol. | 2014-03-13 |
20140073704 | COLLAGEN SCAFFOLDS, MEDICAL IMPLANTS WITH SAME AND METHODS OF USE - The subject invention concerns non-degradable three dimensional porous collagen scaffolds and coatings. These scaffolds can be prepared around sensors for implantation into a body. A specific embodiment of the invention concerns implantable glucose sensors. Sensors comprising a collagen scaffold of the invention have improved biocompatibility by minimizing tissue reactions while stimulating angiogenesis. The subject invention also concerns methods for preparing collagen scaffolds of the invention. The subject invention also concerns sensors that have a collagen scaffold of the invention around the exterior of the sensor. | 2014-03-13 |
20140073705 | BIOABSORBABLE POLYMERIC COMPOSITIONS, PROCESSING METHODS, AND MEDICAL DEVICES THEREFROM - Novel bioabsorbable polymeric blends are disclosed. The blends have a first component that is a polylactide polymers or a copolymer of lactide and glycolide and a second component that is poly(p-dioxanone) polymer. The novel polymeric blends provide medical devices having dimensional stability. Also disclosed are novel bioabsorbable medical devices made from these novel polymer blends, as well as novel methods of manufacture. | 2014-03-13 |
20140073706 | Method for Obtaining an Emulsion Containing an Internal Hydrophobic Phase Dispersed in a Continuous Hydrophilic Phase - The invention relates to a method for producing an emulsion including a hydrophobic internal phase dispersed in a hydrophilic continuous phase, of the medium internal phase (MIPE) or high internal phase (HIPE) type, which has an internal phase percentage higher than 55%, comprising the following steps:
| 2014-03-13 |
20140073707 | COMPOSITIONS COMPRISING A FLUOROSURFACTANT AND A FLUORO-FREE HYDROTROPE - Compositions comprising a fluorosurtactant and a fluoro-free hydrotrope are disclosed. The fluoro-free hydrotropes are cationic aromatic compounds, anionic aromatic compounds, or water soluble azo derivatives. | 2014-03-13 |
20140073708 | SYSTEM FOR MAKING RENEWABLE FUELS INCLUDING GASOLINE, DIESEL, AND JET FUEL - Multiple catalytic processing stations coupled with a system which produces volatile gas streams from biomass decomposition at discrete increasing temperatures or constant temperature. These catalytic processing stations can be programmed to maximize conversion of biomass to jet fuel components. The system may also include a processing station for subjecting biomass within the stations to at least one programmable starting temperature (T | 2014-03-13 |
20140073709 | FLUORINATED COPOLYMER AND ION EXCHANGE MEMBRANE - To provide a fluorinated copolymer which is capable of providing an ion exchange membrane having little adverse effect due to impurities in an alkali chloride aqueous solution on electrolysis of the alkali chloride aqueous solution. To use a fluorinated copolymer of a fluorinated monomer having a carboxylic acid type functional group with a fluorinated olefin, wherein the proportion of components having a common logarithm (log M) of a molecular weight M being from 2.0 to 3.5 is at most 10 mass % per 100 mass % of components having a common logarithm (log M) of a molecular weight M being at least 2.0, contained in a CClF | 2014-03-13 |
20140073710 | REMOVABLE PROTECTIVE TOPCOAT FOR ARTIFICIAL NAIL COATINGS AND METHODS THEREFORE - The present disclosure relates generally to compositions for nail coatings, and particularly, but not by way of limitation, to polymerizable compositions. The disclosure further relates to methods of making a polymerizable, protective and scratch resistant topcoat layer that can be easily removed. | 2014-03-13 |
20140073711 | ADDITIVES IN GYPSUM SLURRIES AND ADJUSTING THEIR PROPORTIONS - A gypsum slurry is provided that includes calcium sulfate hemihydrate; water; a dispersant component comprising at least one of the following a comb-branched polymer with polyether side chains, naphthalene sulfonate-formaldehyde condensate or melamine sulfonate-formaldehyde condensate; a foaming agent; and a polycondensation component with three polycondensation repeating units. Also provided is a method for making a gypsum slurry with a foaming agent in which the ratio between the dispersant component and the polycondensation component is adjusted to control for the size of foam bubbles in the gypsum slurry. Gypsum products made from the gypsum slurry are provided and methods for making the products are provided as well. | 2014-03-13 |
20140073712 | POLYURETHANES COMPRISING HALOGEN COMPOUNDS - The present invention relates to polyurethanes obtainable via mixing of (a) polyisocyanate, (b) polymeric compounds having groups reactive toward isocyanates, (c) catalyst, (d) aliphatic hydrocarbon having from 2 to 15 carbon atoms and comprising at least one heteroatom selected from the group consisting of oxygen, nitrogen, and sulfur, and comprising at least one bromine and/or chlorine atom, (e) optionally blowing agent, (f) optionally chain extender and or crosslinking agent, and (g) optionally auxiliary and/or additives to give a reaction mixture and allowing the reaction mixture to complete its reaction to give the polyurethane, where the aliphatic hydrocarbon (d) comprises no phosphoric ester, polyphosphate, phosphonic ester, or phosphorous ester. The present invention further relates to a process for producing such polyurethanes, and to their use in the interior of conveyances. | 2014-03-13 |
20140073713 | CROSSLINKED POLYMER NANOPARTICLES CONTAINING COMPOSITION, METHOD FOR PREPARING A COPOLYMER USING THE COMPOSITION, AND VINYL CHLORIDE RESIN WITH IMPROVED FOAM MOLDING PROPERTIES - Disclosed is a crosslinked polymer nanoparticle containing composition, a method for preparing a copolymer using the composition, and a vinyl chloride resin with improved foam molding properties. Processing aid in according with the present invention, provides the effects of improved foam molding properties and processibility of a vinyl chloride resin, during a foam molding process upon being added to the vinyl chloride resin. | 2014-03-13 |
20140073714 | Posterior Segment Drug Delivery - A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. A plurality of interconnecting channels can extend from the first side to the second side so as to connect a first a plurality of openings on the first side with a second plurality of openings on the second side. | 2014-03-13 |
20140073715 | Hydrophilic Polymeric Particles and Methods for Making and Using Same - A method of forming a particle includes, in a disperse phase within an aqueous suspension, polymerizing a plurality of mer units of a hydrophilic monomer having a hydrophobic protection group, thereby forming a polymeric particle including a plurality of the hydrophobic protection groups. The method further includes converting the polymeric particle to a hydrophilic particle. | 2014-03-13 |
20140073716 | PHOTOCURABLE DIANHYDRO-HEXANE-HEXOL DERIVATIVE, MANUFACTURING METHOD THEREOF, AND PHOTOCURABLE COMPOSITION INCLUDING SAME - Provided herein is a photocurable dianhydrohexanehexol derivative, a method preparing the same, and a composition including the same, for example, to a photocurable compound derived from environmentally friendly biomass, the compound having a structure where a 2-hydroxypropyl methacrylate (HPM) functional group prepared by reacting a biomass derived dianhydrohexanehexol (1,4:3,6-dianhydro-d-hexane-1,2,3,4,5,6-hexol, DHH) compound under an optimal reaction condition is combined, a preparing method thereof, and a photocurable composition comprising the photocurable compound. | 2014-03-13 |
20140073717 | PHOTOREACTIVE POLYMER - A description is given of a photoreactive polymer preparable by radical polymerization using at least one photoreactive monomer, where the photoreactive monomer has at least one radically polymerizable C—C double bond, at least one hydrophilic group selected from an ethylene glycol group and polyethylene glycol groups having at least 2 ethylene glycol units, and at least one photoreactive group, the photoreactive group being a photoenolizable carbonyl group. | 2014-03-13 |
20140073718 | MULTIPLE MEMBRANES FOR REMOVING VOC'S FROM LIQUIDS - The present invention relates to a process for removing volatile organic compounds (VOCs) from a liquid stream using multiple membranes that are permeable to the VOCs but impermeable to the liquid. | 2014-03-13 |
20140073719 | SYNTHESIS OF SUPERHYDROPHOBIC COPOLYMER USING CARBON DIOXIDE SOLVENT AND APPLICATION THEREOF - A method for preparing a superhydrophobic random copolymer using a carbon dioxide solvent, and more particularly, to a method for preparing a surface coating copolymer having a superhydrophobic performance by radical copolymerization of a hydrocarbon monomer, and a silicone monomer or a fluorinated monomer using a supercritical carbon dioxide solvent as a copolymerization solvent. | 2014-03-13 |
20140073720 | SILOXANE ORGANIC HYBRID MATERIALS PROVIDING FLEXIBILITY TO EPOXY-BASED COATING COMPOSITIONS - Disclosed herein are epoxy-based compositions that include a polysiloxane flexibilizer and amino-functional alkoxysilane, which provides flexibility, hardness and gloss to such compositions and that are useful as coatings, adhesives, sealants and composites. Also disclosed are cured compositions and substrates coated with such epoxy-based compositions. | 2014-03-13 |
20140073721 | RESIN COMPOSITION, PREPREG AND RESIN SHEET AND METAL FOIL-CLAD LAMINATE - A resin composition is provided which can be suitably used in a printed circuit board having excellent electrical properties, heat resistance and peel strength, with flame retardancy maintained, a prepreg and resin sheet which use the same, and a metal foil-clad laminate which uses the prepreg. A resin composition including a polyphenylene ether (A), a specific phosphorus-containing cyanate ester compound (B), a non-halogenated epoxy resin (C), a cyanate ester compound (D) and a filler (E) is used. | 2014-03-13 |
20140073722 | CELLULOSE NANOFIBERS AND METHOD FOR PRODUCING SAME, COMPOSITE RESIN COMPOSITION, MOLDED BODY - Cellulose nanofibers have an average degree of polymerization of 600 or more to 30000 or less, an aspect ratio of 20 or more to 10000 or less, an average diameter of 1 nm or more to 800 nm or less, and an Iβ-type crystal peak in an X-ray diffraction pattern, in which a hydroxyl group is chemically modified by a modifying group. | 2014-03-13 |
20140073723 | Phase Change Ink with Compostable Wax - Disclosed is a phase change ink comprising: (a) an ink carrier comprising a compostable paraffin or polymethylene wax; and (b) a colorant. | 2014-03-13 |
20140073724 | THERMOPLASTIC POLYIMIDE AS FLOW PROMOTER AND FLAME RETARDANT SYNERGIST FOR FILLED POLYAMIDE COMPOSITIONS - Disclosed herein are compositions comprising polyamides, thermoplastic polyimides, and inorganic fillers. The compositions can also comprise a flame retardant additive. Also disclosed are materials and devices made thereof. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 2014-03-13 |
20140073725 | POLY(PHENYLENE ETHER) COMPOSITION, ARTICLE, AND METHOD - A composition includes specific amounts of a poly(phenylene ether)-polysiloxane block copolymer reaction product and an impact modifier. The poly(phenylene ether)-polysiloxane block copolymer reaction product includes a poly(phenylene ether) and a poly(phenylene ether)-polysiloxane block copolymer. The composition exhibits a desirable balance of impact strength, heat resistance, and flame retardancy while minimizing or excluding flame retardant additives such as organophosphate esters and halogenated flame retardants. | 2014-03-13 |
20140073726 | RESIN COMPOSITION AND RESIN MOLDED ARTICLE - There is provided a resin composition containing: a polycarbonate resin; an acrylonitrile/butadiene/styrene resin, a polylactic acid resin, at least one flame retardant selected from a condensed phosphate and a phosphazene compound, and talc modified with an acid; and provided a resin molded article containing: a polycarbonate resin; an acrylonitrile/butadiene/styrene resin; a polylactic acid resin; at least one flame retardant selected from a condensed phosphate and a phosphazene compound; and talc modified with an acid. | 2014-03-13 |
20140073727 | CHLOROPRENE RUBBER AND CHLOROPRENE RUBBER COMPOSITION - Provided is a chloroprene rubber superior in the effectiveness of preventing mold staining. | 2014-03-13 |
20140073728 | SOLID MARKING COMPOSITION - This invention relates to a solid marking composition comprising at least one resin, at least one pigment, at least one dispersant, at least one solvent, and a gelling agent. This invention also provides a method of making the solid marking composition. | 2014-03-13 |
20140073729 | Infrared-Reflecting Pigment Based on Titanium Dioxide, and a Method for Its Manufacture - The invention relates to rutile titanium dioxide pigment particles that are capable of reflecting infrared radiation to a high degree and also display pigmenting properties, as well as a method for their manufacture. The particles have a mean particle size of 0.4 to 1.0 μm and are doped with zinc and potassium, but not with aluminium. Preferably, the particles have a compact particle form with a preferred height:width ratio of 1.5:1. The particles are preferably manufactured by the familiar sulphate process for manufacturing titanium dioxide, and are optionally subjected to inorganic and/or organic post-treatment following calcining. Preferably, the rutile titanium dioxide particles are suitable for manufacturing heat-insulating paints, coatings or plastics as well as for instance plasters or paving stones. | 2014-03-13 |
20140073730 | POLYPROPYLENE-BASED RESIN COMPOSITION AND MOLDED ARTICLE MADE THEREOF - A polypropylene-based resin composition capable of affording a molded article superior in tensile elongation at break includes a polypropylene resin (A), an ethylene-α-olefin copolymer (B) having a density of 0.865 to 0.890 g/cm | 2014-03-13 |
20140073731 | HIGH IMPACT POLYPROPYLENE COMPOSITIONS - Disclosed are fiber reinforced thermoplastic compositions exhibiting rigidity and improved impact resistance. The disclosed compositions comprise a polypropylene polymer component; a low melt flow elastomer component; and a fiber reinforcement component. Also disclosed are method for the manufacture of the disclosed compositions and various methods for the use thereof. | 2014-03-13 |
20140073732 | PHENOLIC RESIN MOLDING COMPOUND - A phenolic resin molding compound includes (A) a novolac-type phenolic resin including an alkylbenzene-modified novolac-type phenolic resin, (B) a resol-type phenolic resin, (C) hexamethylenetetramine, (D) graphite, and (E) fiber-shaped filler, wherein in regard to the content of each component on the basis of the entirety of the molding compound, a total content of the components (A) to (C) is 30 to 40% by weight, a content of the component (D) is 30 to 50% by weight, and a content of the component (E) is 5 to 20% by weight. | 2014-03-13 |
20140073733 | Pressure-Sensitive Adhesive Composition for Optical Member and Processed Product Thereof - A pressure-sensitive adhesive composition for an optical member is obtained by blending 100 parts by weight of an acrylic polymer, which contains 80 to 98.7 parts by weight of (a) a monomer constituted of an alkyl acrylate monomer having an alkyl group of 1 to 12 carbon atoms and/or an aromatic ring-containing acrylic monomer, 0.2 to 1.5 parts by weight of (b) an amide group-containing acrylic monomer and 1 to 5 parts by weight of (c) a hydroxyl group-containing acrylic monomer, with 0.12 to 1 part by weight of (d) an isocyanate-based curing agent having an isocyanurate skeleton as a curing agent, and is characterized by substantially containing no metal chelate-based curing agent. Accordingly, a pressure-sensitive adhesive composition, which has excellent heat resistance and wet heat resistance and whose aging time can be particularly shortened, is provided. | 2014-03-13 |
20140073734 | DYNAMIC LOAD-ABSORBING MATERIALS AND ARTICLES - A compound for protection of an object from a blast or shock wave. The compound include a matrix material and at least a first and second sets of inclusions in the matrix material that differ in size, quantity, shape and/or composition in a direction through the impact-absorbing material, the combination of which contributes to the ability of the material to exhibit at least one property that changes as the inclusions are deformed in response to a blast or shock wave. | 2014-03-13 |